411 related articles for article (PubMed ID: 27991934)
1. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
2. RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.
Eckfeldt CE; Pomeroy EJ; Lee RD; Hazen KS; Lee LA; Moriarity BS; Largaespada DA
Oncotarget; 2016 Oct; 7(40):65147-65156. PubMed ID: 27556501
[TBL] [Abstract][Full Text] [Related]
3. Targeting Ras signaling in AML: RALB is a small GTPase with big potential.
Pomeroy EJ; Eckfeldt CE
Small GTPases; 2020 Jan; 11(1):39-44. PubMed ID: 28682649
[TBL] [Abstract][Full Text] [Related]
4. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
7. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
[TBL] [Abstract][Full Text] [Related]
8. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
Kim WI; Matise I; Diers MD; Largaespada DA
Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
[TBL] [Abstract][Full Text] [Related]
9. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
Xue L; Pulikkan JA; Valk PJ; Castilla LH
Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
[TBL] [Abstract][Full Text] [Related]
10. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
[TBL] [Abstract][Full Text] [Related]
11. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
12. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
13. Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.
Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Ghali HH; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Sughayer MA; Rihani R; Madanat FF; Inoshita T; Kamata M; Koike K
Pediatr Blood Cancer; 2015 Dec; 62(12):2157-61. PubMed ID: 26222068
[TBL] [Abstract][Full Text] [Related]
14. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
[TBL] [Abstract][Full Text] [Related]
15. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
16. NRAS mutations in de novo acute leukemia: prevalence and clinical significance.
Dunna NR; Vuree S; Anuradha C; Sailaja K; Surekha D; Digumarti RR; Rao VR; Yadav SK; Reddy R; Vishnupriya S
Indian J Biochem Biophys; 2014 Jun; 51(3):207-10. PubMed ID: 25204082
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Nonami A; Sattler M; Weisberg E; Liu Q; Zhang J; Patricelli MP; Christie AL; Saur AM; Kohl NE; Kung AL; Yoon H; Sim T; Gray NS; Griffin JD
Blood; 2015 May; 125(20):3133-43. PubMed ID: 25833960
[TBL] [Abstract][Full Text] [Related]
18. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
[TBL] [Abstract][Full Text] [Related]
19. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
20. TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.
Pang Y; Zhao Y; Wang Y; Wang X; Wang R; Liu N; Li P; Ji M; Ye J; Sun T; Li J; Ma D; Lu F; Ji C
J Exp Clin Cancer Res; 2020 Aug; 39(1):158. PubMed ID: 32795319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
